PolyPid Secures FDA Waiver for Drug Application
PolyPid Ltd., a biopharmaceutical company, announced on March 17, 2026, that the U.S. Food and Drug Administration (FDA) granted a small business waiver of the Prescription Drug User Fee Act (PDUFA) fee, amounting to approximately $4.3 million, for the New Drug Application (NDA) of its lead product candidate D-PLEX100, which targets the prevention of surgical site infections in abdominal colorectal surgeries, according to GlobeNewswire PE. This waiver enables the company to focus resources on commercialization preparations following the successful Phase 3 SHIELD II trial, which demonstrated a 60% relative risk reduction in surgical site infections.
Details of the Waiver and NDA Submission
The FDA’s waiver, issued as PolyPid prepares to submit the first sections of its rolling NDA by the end of March 2026, follows positive feedback from the FDA during a pre-NDA meeting in December 2025, as stated in the announcement. PolyPid, listed on Nasdaq as PYPD, is using this financial relief to advance toward market entry for D-PLEX100, which involves local prolonged release of the antibiotic doxycycline via their Kynatrix technology for up to 30 days to prevent infections, including those from antibiotic-resistant bacteria. The company remains on track for NDA submission, building on the SHIELD II trial’s achievement of primary and key secondary endpoints.
Background on D-PLEX100 and Company Progress
D-PLEX100, PolyPid’s lead candidate, is designed for administration at surgical sites to provide continuous antibacterial activity, as detailed in the source material. The Phase 3 SHIELD II trial showed a statistically significant 60% relative risk reduction in SSI incidence for abdominal colorectal surgeries with large incisions. PolyPid’s CEO, Dikla Czaczkes Akselbrad, noted that the waiver comes days before the planned NDA submission, allowing the company to progress in commercial partnership discussions for the U.S. market, according to GlobeNewswire PE. As widely-known context, the PDUFA program funds FDA drug reviews, and waivers for small businesses like PolyPid can alleviate financial burdens during development.
Implications for PolyPid’s Future
PolyPid is in advanced stages of preparing for commercialization, including ongoing discussions for U.S. market partnerships, as the company expects 2026 to be transformative. The Kynatrix technology pairs with doxycycline to ensure high local drug concentrations, addressing unmet needs in surgical infection prevention. This development follows the company’s dedication to improving patient outcomes, with the SHIELD II trial results underscoring their progress, according to GlobeNewswire PE.
